Brain-Computer Interfaces Are Leaving the Lab
- 11 minutes ago
- 4 min read
Overview
In a recent conversation with Y Combinator, Max Hodak, co-founder of Neuralink and founder of Science, argues that brain–computer interfaces are crossing from research into real-world impact, driven by compounding advances in hardware, AI, and biology. Breakthroughs like restored vision show these systems can now produce meaningful perception. He frames the brain as an interfaceable system, where neural input and output can be written and read to restore and eventually extend human capabilities. Brain plasticity allows these systems to work without perfect decoding, pointing toward a future where neuroscience and engineering reshape how humans interact with technology.
The Inflection Point: From Incremental to Nonlinear
Biotech has historically moved slowly. Decade-long cycles, marginal improvements, high failure rates.
Hodak’s view that pattern is breaking.
BCIs are moving from theory to real clinical impact
Engineering is replacing trial-and-error drug discovery
Progress is compounding across hardware, AI, and biology
Something new has happened.
And most people are underestimating it.
Restoring Vision Isn’t a Theory Anymore
One of the clearest signals: restoring sight is now working.
Science’s retinal implant, a 2mm chip placed under the retina, bypasses damaged photoreceptors and directly stimulates the visual system.
Patients who were blind for years can read letters again
The brain reconstructs actual images, not just light flashes
Clinical trials across Europe showed strong results
This matters because previous attempts failed at the same problem.
Earlier systems produced signals. This produces vision.
The difference is architectural: stimulating earlier in the visual pipeline preserves how the brain expects to receive information.
The Real Insight: The Brain Has an API
Max frames the brain like a system with defined interfaces.
All input and output flows through:
Cranial nerves
Spinal cord
In that sense, reality is just signals.If you can write to those signals, you can:
Restore lost functions (vision, hearing, movement)
Potentially create new ones
BCIs are not just medical devices, they are interfaces into the brain’s input/output layer.
Why BCIs Are a Category, Not a Product
One misconception: there will be a single “BCI product.” Max Hodak rejects that.
BCIs will look more like pharma:
Different technologies for different use cases
Implants, ultrasound, optogenetics, biohybrids
Medical-first, consumer later
Near term:
Severe disabilities (blindness, paralysis)
Long term:
Cognitive modulation (focus, sleep)
New forms of interaction
The constraint is not imagination. It’s risk–reward.
Plasticity Changes the Game
A key overlooked factor: the brain adapts.
Patients can learn to control neurons directly
The brain rewires under feedback
Even arbitrary signals can become meaningful
In early experiments, researchers didn’t decode intent. They fixed mappings and let the brain learn.
It worked. This flips the paradigm:
You don’t need perfect decoding. You need a feedback loop the brain can optimize.
Beyond Restoration: Engineering the Brain
Most current applications restore lost function.
The next phase is structural:
Adding new pathways
Creating new “senses”
Modifying how the brain processes information
Hodak points to biohybrid interfaces, implants seeded with living neurons that integrate into the brain, as a path toward high-bandwidth connectivity.
The analogy is direct:
Not wires into the brain. New biological connections.
AI and Neuroscience Are Converging
One of the more subtle insights: AI is helping decode the brain.
Neural networks and biological brains are converging around similar concepts:
Representations
Latent spaces
Hierarchical processing
In some cases, AI is now ahead.
Instead of neuroscience informing AI,
AI is becoming a tool to understand the brain.
The Economics of Medicine Are Breaking
A recurring theme in Hodak’s thinking: many medical limits are not scientific, but economic.
Example:
Life-support systems can keep patients alive indefinitely
But cost and complexity make it impractical
The gap is between what’s possible and what’s deployable. BCIs, combined with advances in hardware and systems design, compress that gap. Engineering replaces cost barriers.
The Takeoff Era
Hodak’s long-term view:
BCIs + AI redefine the human condition
Intelligence becomes abundant
Interfaces between humans and machines — and between humans themselves — evolve
His most provocative claim:
The first people to live to 1,000 may already be alive.
Not because of a single breakthrough, but because multiple curves are compounding at once.
The Unfamiliar Direction of Progress
BCIs are often framed as an AI-adjacent story. Hodak reframes it as a healthcare, longevity, consciousness story.
The endpoint isn’t just better tools. It’s a redefinition of perception, capability, the boundary of the self.
The Real Question
BCIs are still early. Bandwidth is low. Surgery is invasive. Applications are narrow.
But the direction is clear:
If the brain is the only organ that fundamentally matters, and if we are getting better at engineering it, then the question is not whether BCIs scale. It’s how far they go.
And how quickly the rest of the world catches up to what’s already possible. Watch the full interview on YouTube
Max Hodak currently CEO of Science, a biology-driven technology company focused on the brain. Previously, he helped start Neuralink, where he served as President from inception through early 2021, and Transcriptic, a robotic cloud laboratory for the life sciences, where he was CEO for the first five years. He graduated from Duke University's Pratt School of Engineering in May 2012 after averaging 128,550 miles flown each of the prior two years commuting between full-time work in California, and school and research in North Carolina. He's been programming since he was five or six, and he eagerly looking forward to a world more bits than atoms.
With dozens of patients in six countries enrolled in our ongoing clinical studies, we are committed to translating innovations from bench to bedside for the benefit of everyone.
We work to restore quality of life to those with debilitating conditions for which there are no treatment options, creating devices aimed at restoring vision, cognition, and mobility to patients who have lost it. To support progress across our industry, we provide state-of-the-art components and vertically integrated infrastructure for others to build on via Science Foundry.
Headquartered in Alameda, California, we are a global company with secondary offices in Research Triangle Park, North Carolina and Paris, France.
Our brain-computer interface translates neural signals into actions. In our clinical trials, people are using Neuralink devices to control computers and robotic arms with their thoughts.
This technology will restore autonomy to those with unmet medical needs and unlock new dimensions of human potential.
Comments